RefleXion Medical adds Renee Ryan, Dr. Rana Al-Hallaq and Alice Schroeder to its Board of Directors

– USA, CA –  RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy as a new modality for treating all stages of cancer, today announced the appointments of Renee Ryan, Dr. Rana Al-Hallaq, Ph.D., and Alice Schroeder to its Board as external directors.

Schroeder was also appointed chairperson of the Audit Committee. Al-Hallaq serves as a designee of Pfizer Inc.

“I am extremely pleased to welcome Renee, Rana and Alice to our board of directors as we transition to a commercial stage company,” said CEO, Todd Powell. “They also join RefleXion at the beginning of our clinical adoption in the U.S. as we have recently begun treating patients with conventional radiotherapy, the first step in our vision of delivering BgRT for late-stage cancer treatment. Each one brings impeccable credentials, including a wealth of financial, investment, health technology, and pharmaceutical industry experience. I look forward to their dedication, leadership and commitment to our vision.”

About Renee Ryan

Ryan is CEO of Cala Health, a bioelectronic medicine company transforming the standard of care for chronic diseases, such as essential tremor, by merging innovations in neuroscience and technology. Under Ryan’s guidance, Cala Health is vertically integrating its commercial model to reshape the delivery of prescription therapies. Before Cala Health, she led the health technology investments for Johnson & Johnson Innovation on the West Coast and the Asia Pacific for eight years. Previously, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs.

Ryan holds a Bachelor of Arts degree from Georgetown University and an MBA from Columbia University.

About Dr. Rana Al-Hallaq

Al-Hallaq is executive director and a partner at Pfizer Ventures, where she leverages her clinical and business development experience to assess, invest in, and manage equity investments. Beyond RefleXion, she has responsibility for Pfizer’s investments in Mitokinin, Autifony Therapeutics, Blade Therapeutics, Arkuda, Montis, Biograph55 and VectivBio, among others. Her experience at Pfizer also includes negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Before joining Pfizer, she held roles at Allergan in Clinical Development Psychiatry and Business Development.

Al-Hallaq holds a Bachelor of Arts in Biology from Hamilton College and a Ph.D. in Neuroscience from Georgetown University.

About Alice Schroeder

Schroeder currently serves on the board of insurer/asset manager Prudential plc, where she chairs Responsibility and Sustainability and is a member of the Risk and Audit committees. She also chairs the Nominating and Governance Committee and serves on the Audit and Compliance and Quality committees for Natus Medical. She is a former CPA, Wall Street analyst, banker, and portfolio director, and has held positions with Morgan Stanley, CIBC Oppenheimer, PaineWebber, and Ernst & Young. Schroeder was the former CEO of WebTuner, a tech startup that exited through sale to a strategic investment group. She holds a Bachelor of Arts in Business Administration and an MBA from the University of Texas at Austin.

About RefleXion Medical

RefleXion Medical is a privately held commercial-stage company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. BgRT incorporates positron-emission tomography imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.

For more information: https://reflexion.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.